RCi202, BC145c6

General

Cell Line

hPSCreg name PFIZi019-A
Cite as:
PFIZi019-A (RRID:CVCL_RF98)
Alternative name(s)
RCi202, BC145c6
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
PFIZi017-A
(BC142c7, RCi209)
Donor's gene variants:
SCN1A, SCN1A
Donor diseases:
Dravet syndrome
PFIZi014-A
(OD002-s7)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi021-A
(OD001-s7)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi009-A
(RCi188)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi018-A
(BC143c8, RCi207)
Donor's gene variants:
SCN1A, SCN1A
Donor diseases:
Dravet syndrome
PFIZi015-A
(OD003-s5)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi016-A
(OD005-s9)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
UKBi010-A
(iLB-DS-95f-r8)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
INSRMi004-A
(PC118_c7)
Donor's gene variants:
SCN1A
Donor diseases:
epilepsy
IMBAi018-A
(622_DS04 #1)
Donor diseases:
Dravet Syndrome
IMBAi020-A
(624_DS40 #8)
Donor diseases:
Dravet Syndrome
KAIMRCi003-A
(DRVT-iPSC#1)
Donor's gene variants:
SCN9A, CPLX1
Donor diseases:
Dravet Syndrome
KAIMRCi003-B
(DRVT-iPSC#2)
Donor's gene variants:
SCN9A, CPLX1
Donor diseases:
Dravet Syndrome
IMBAi019-A
(623_DS22 #10)
Donor diseases:
Dravet Syndrome
Last update 10th March 2020
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Pfizer Limited - Pfizer (PFIZ)
Distributors

External Databases

BioSamples SAMEA4458852
Cellosaurus CVCL_RF98
Wikidata Q54947274

General Information

Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 5-9

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • SMEI
  • Severe myoclonus epilepsy of infancy
  • Severe myoclonic epilepsy of infancy
Genetic variants
SCN1A (target)
2q24.3
SCN1A Variant 1:1 bp deletion of T ; Nucleotide Postion 4522' Codon Position: 1508; Amino Acid Change- Frame Shift
Disease associated phenotypes
  • Myoclonic seizures
  • Slightly wide-based gait, intermittent ataxia

External Databases (Donor)

BioSamples SAMEA4458853

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Provide contact information of the holder of the original Donor Information Sheet: Anjanette Burns / Dr Orrin Devinsky
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Dravet Syndrome / Epilepsy
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? Yes

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? NYU Institutional Review Board
Approval number i14-01725
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? NYU Institutional Review Board
Approval number i14-01725
Do you have obligations to third parties in regard to the use of the cell line? Yes
Please describe: Restricted to research into Dravet Syndrome/Epilepsy
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? Yes
Further constraints on use Restricted to research into Dravet Syndrome/Epilepsy
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
A nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
Synonyms
  • normoblast
Age of donor (at collection) 5-9

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SSEA-1
No
TRA 1-60
Yes
SSEA-4
Yes
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
SOX17
Yes
GATA6
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
MIXL1
Yes
NCAM1
Yes
VIM
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
PAX6
Yes
HES5
Yes
NeuroD1
No

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage: 19

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
No autosomal or sex chromosome aneuploidies were detected
Passage number: 19
Karyotyping method: KaryoLite BoBs

Other Genotyping (Cell Line)